Last reviewed · How we verify
Oxycodone, Paroxetine, and Quetiapine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Oxycodone, Paroxetine, and Quetiapine (Oxycodone, Paroxetine, and Quetiapine) — Food and Drug Administration (FDA).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Oxycodone, Paroxetine, and Quetiapine TARGET | Oxycodone, Paroxetine, and Quetiapine | Food and Drug Administration (FDA) | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Oxycodone, Paroxetine, and Quetiapine CI watch — RSS
- Oxycodone, Paroxetine, and Quetiapine CI watch — Atom
- Oxycodone, Paroxetine, and Quetiapine CI watch — JSON
- Oxycodone, Paroxetine, and Quetiapine alone — RSS
Cite this brief
Drug Landscape (2026). Oxycodone, Paroxetine, and Quetiapine — Competitive Intelligence Brief. https://druglandscape.com/ci/oxycodone-paroxetine-and-quetiapine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab